Autoimmune drug discovery is gaining attention as ICMR backs a four-year Indian study exploring genetic links and shared treatment targets across affected families nationally.
AIIMS Nagpur secures Rs 30 crore for a Biosafety Level III laboratory, strengthening Maharashtra’s pathogen detection and infectious disease preparedness.
Indian CDMO players are expanding complex-product manufacturing as Sai Life Sciences and OneSource Specialty Pharma target higher-value global outsourcing opportunities.
Microsoft’s step-by-step AI outperforms doctors in complex cases, improving diagnostic accuracy while reducing unnecessary tests and healthcare costs.
In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Pradeep Patni, Chief Executive Officer at Celagenex LLC, discusses how a data-driven pharma strategy can help pharmaceutical companies identify growth opportunit
Roche Q3 CEETRIS growth highlights India’s strategic importance as the company’s International region expands and demand for specialty medicines rises.
Pharma giants pour billions into Chinese innovation, securing advanced oncology platforms, AI-powered clinical trials, and next-generation drug-delivery technologies.
India’s pharmaceutical sector is seeing major developments in drug pricing, cancer treatment, manufacturing, and international market expansion. The Centre has notified a 30 percent trade-margin cap on 137 anti-cancer drugs, while Lupin has...
.jpeg)
India’s Rs 50 crore drug discovery funding under the PRIP scheme targets startups and MSMEs developing indigenous medicines. Applications close on 10 November 2026.
Vir Biotechnology and Gilead Sciences have signed a potential USD 1.9 billion deal to develop three dual-masked T-cell engager candidates for solid tumours.
.jpg)
, CDSCO.jpg)
